"Didanosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
| Descriptor ID |
D016049
|
| MeSH Number(s) |
D03.633.100.759.590.616.130 D13.570.230.500.090 D13.570.583.616.130 D13.570.800.573.130
|
| Concept/Terms |
Didanosine- Didanosine
- Dideoxyinosine
- 2',3'-Dideoxyinosine
- 2',3' Dideoxyinosine
- ddI (Antiviral)
|
Below are MeSH descriptors whose meaning is more general than "Didanosine".
Below are MeSH descriptors whose meaning is more specific than "Didanosine".
This graph shows the total number of publications written about "Didanosine" by people in this website by year, and whether "Didanosine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Didanosine" by people in Profiles.
-
A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. Pediatr Infect Dis J. 2006 Jan; 25(1):59-64.
-
Brain virus burden and indoleamine-2,3-dioxygenase expression during lentiviral infection of rhesus monkey are concomitantly lowered by 6-chloro-2',3'-dideoxyguanosine. Eur J Neurosci. 2004 Jun; 19(11):2997-3005.
-
Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine. Pediatr Infect Dis J. 2000 Nov; 19(11):1083-6.
-
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother. 2000 Apr; 44(4):1029-34.
-
Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. Pediatrics. 1999 May; 103(5):e62.
-
Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211). Clin Diagn Lab Immunol. 1999 May; 6(3):311-5.
-
Advanced testicular germ cell tumor in a hemophilic patient with human immunodeficiency virus infection. Jpn J Clin Oncol. 1998 Sep; 28(9):567-70.
-
A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr. 1998 Mar; 132(3 Pt 1):543-6.
-
Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics. 1996 Jun; 97(6 Pt 1):886-90.
-
Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. Antimicrob Agents Chemother. 1995 Jun; 39(6):1259-64.